Inmune Bio, Inc. (INMB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.33+0.76%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · INMB
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in Q1, 2027 and EU EMA in 2027, alongside a planned U.S.…
Stated in 3 of 3 supplied quarters. Management reported: “Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in Q1, 2027 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.” “Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.” Operating income was $-1.476 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in Q1, 2027 and EU EMA in 2027, alongside a planned U.S.…”
“Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Bio…”
“INmune Bio has three product platforms: (1) CORDStrom™, a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blind…”
Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive regist…
Stated in 3 of 3 supplied quarters. Management reported: “Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.” “We are positioned to execute the Phase 2b/3 as a precision-medicine registrational program.”
“Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive regist…”
“Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive regist…”
“We are positioned to execute the Phase 2b/3 as a precision-medicine registrational program.”
The gross proceeds to the Company from the Offering are expected to be approximately $4.50 million, before deducting placement agent fees and other estimated offering expenses.
Stated in 2 of 3 supplied quarters. Management reported: ““Receiving approximately $4.6 million in non-dilutive cash during June and July strengthens our financial position, extends our runway without issuing additional equity and allows us to preserve momentum across the near-term regulatory and clinical milestones that we believe can drive substantial value.” “The gross proceeds to the Company from the Offering are expected to be approximately $4.50 million, before deducting placement agent fees and other estimated offering expenses.”
“The gross proceeds to the Company from the Offering are expected to be approximately $4.50 million, before deducting placement agent fees and other estimated offering expenses.”
““Receiving approximately $4.6 million in non-dilutive cash during June and July strengthens our financial position, extends our runway without issuing additional equity and allows us to preserve mome…”
Use research and development rebates to strengthen the balance sheet and support clinical and regulatory milestones without issuing additional equity.
Prepare and submit Marketing Authorization Applications in UK, EU, and US for CORDStrom (Ebstrocel) in recessive dystrophic epidermolysis bullosa (RDEB).
Over the trailing year it converted 0.61x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
21 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-04.